BioBrief

BioBrief

0.0 (0)
Business
Daily Series

BioBrief is a daily biotech and biopharma news update.

Episode 1

Weds, April 22: Amneal Buys Kashiv, Roche Advances Fenebrutinib, and Merck Bets on AI

Today on BioBrief: Amneal moves into biosimilars with its Kashiv acquisition,Roche submits fenebrutinib for multiple sclerosis review, and Merck commits up to $1 billion to Google Cloud AI infrastructure.

4 min
Episode 2

Thursday, April 23: Regeneron’s Gene Therapy Breakthrough, Novo’s Pediatric Semaglutide Win, and Grace’s FDA Setback

BioBrief — Thursday, April 23 Today’s episode covers three major biopharma developments: Regeneron’s FDA-approved gene therapy for inherited hearing loss, Novo Nordisk’s positive pediatric semaglutide data, and Grace Therapeutics’ FDA setback on its stroke drug. The common thread is that each story shifts regulatory probability, but in different directions: one clears a major hurdle, one expands an existing franchise, and one runs into manufacturing and toxicology friction. 1) Regeneron gene therapy approval The FDA approved Regeneron’s gene therapy for inherited hearing loss, marking the first approval in this category. The therapy, Otarmeni, is a dual AAV gene therapy that replaces the defective OTOF gene, which is needed for sound signal transmission in the inner ear. The approval was based on a small single-arm study, but the efficacy signal was strong, with most patients showing measurable hearing improvement. Safety looked manageable, and the main significance is platform validation for inner-ear gene therapy rather than near-term revenue. 2) Novo Nordisk pediatric semaglutide data Novo Nordisk reported positive phase three data for oral semaglutide in children and adolescents with type 2 diabetes. In a randomized placebo-controlled study, the drug produced a meaningful HbA1c reduction at 26 weeks, with safety consistent with prior semaglutide data. This supports broader lifecycle expansion for semaglutide beyond adults and strengthens Novo’s competitive position in GLP-1s. The next catalyst is regulatory filing and label expansion. 3) Grace Therapeutics FDA letter Grace Therapeutics received a complete response letter for GTX-104, its intravenous nimodipine product for stroke-related complications. The FDA’s concerns were centered on manufacturing, packaging, and toxicology risk assessment rather than efficacy. The clinical data had shown lower hypotension risk and improved dosing consistency versus oral nimodipine, but the regulatory delay increases execution and financing risk. The company now needs a Type A meeting with the FDA to determine the fastest path forward.

4 min
Episode 3

Friday, April 24: Regeneron’s First Gene Therapy Approval, Sanofi’s MS Win, Compass Gets Faster Psychedelic Review, and Arrowhead Advances

BioBrief — Friday, April 24. Today’s episode covers four major biopharma developments: Regeneron’s FDA approval of the first gene therapy for genetic hearing loss, Sanofi’s positive CHMP opinion for progressive MS, Compass Pathways’ faster FDA review path for psilocybin, and Arrowhead’s positive European opinion for a rare-disease siRNA therapy. Regeneron’s Otarmini becomes the first approved gene therapy for severe genetic hearing loss caused by OTOF mutations. In the CHORD trial, 16 of 20 efficacy patients met the main hearing-improvement endpoint at 24 weeks, with five of 12 reaching normal hearing on longer follow-up. The main significance is platform validation for inner ear gene therapy.Sanofi’s tolebrutinib received a positive CHMP opinion for non-relapsing secondary progressive MS. In HERCULES, the drug reduced six-month confirmed disability progression by 31% versus placebo, but liver safety remains the main concern. Europe is moving closer to approval, while the U.S. remains constrained.Compass Pathways received rolling NDA review and a Commissioner’s National Priority Voucher for COMP360, its synthetic psilocybin program for treatment-resistant depression. Two Phase 3 studies showed consistent though modest benefit, with statistically significant improvements over placebo or control. The key questions now are timing, labeling, and reimbursement.Arrowhead’s plozasiran received a positive CHMP opinion for familial chylomicronemia syndrome. In the main study, triglycerides fell 80% after ten months versus 17% on placebo, with fewer pancreatitis cases. This supports both the drug and the broader RNAi platform.Today’s stack: Regeneron first, Sanofi second, Compass third, Arrowhead fourth.

6 min
Episode 4

Monday, April 27: Intellia’s CRISPR Win, Sun’s Organon Deal, and Oruka’s Psoriasis Data

BioBrief covers the highest-signal biopharma developments from Monday, April 27th. Today’s episode focuses on Intellia’s Phase 3 in vivo CRISPR data, Sun Pharma’s $11.75 billion Organon acquisition, Oruka’s Phase 2a psoriasis readout, and Jazz’s FDA Priority Review catalyst in HER2-positive gastroesophageal cancer. Intellia / lonvo-zMechanism: one-time in vivo CRISPR edit of KLKB1 to reduce kallikrein activityIndication: hereditary angioedemaStage: Phase 3; rolling BLA startedKey result: 87% attack reduction versus placebo; 62% attack-free and therapy-free versus 11% on placeboWhy it matters: randomized Phase 3 data materially improve approval probability for a one-time gene-editing therapy, though commercial uptake must compete with effective chronic drugs.Sun Pharma / OrganonMechanism: corporate acquisition, not a drug mechanismIndication: women’s health, biosimilars, and established brands portfolioStage: definitive agreementKey result: $11.75 billion all-cash transaction at $14 per shareWhy it matters: the deal could roughly double Sun’s revenue and EBITDA, but brings integration risk and Organon’s $8.6 billion net debt.Oruka / ORKA-001Mechanism: extended half-life IL-23p19 antibodyIndication: moderate-to-severe plaque psoriasisStage: Phase 2aKey result: 63.5% PASI 100 at week 16; about 83% PASI 90; 84 patients enrolledWhy it matters: strong efficacy makes ORKA-001 more credible, but the commercial thesis depends on durable clearance with infrequent dosing.Jazz / zanidatamabMechanism: bispecific HER2 antibodyIndication: first-line HER2-positive gastroesophageal adenocarcinomaStage: FDA Priority ReviewKey result: progression-free survival of 12.4 months versus 8.1 months; triplet overall survival of 26.4 months versus 19.2 monthsWhy it matters: zanidatamab could challenge trastuzumab as the HER2 backbone in first-line gastroesophageal cancer.Today’s stack: Intellia first, Sun Pharma second, Oruka third, Jazz fourth.

5 min
Episode 5

Tuesday, April 28: Survodutide’s Obesity Data, Bepirovirsen’s FDA Review, and Lilly’s Editing Deal

Today’s BioBrief covers a Phase 3 obesity readout, a major chronic hepatitis B regulatory update, and a large genetic medicine platform deal. We also look at Scancell’s melanoma vaccine signal and zipalertinib’s FDA review in EGFR exon 20 lung cancer. Boehringer Ingelheim / Zealand Pharma — survodutideMechanism: dual glucagon / GLP-1 receptor agonistIndication: obesity or overweight without type 2 diabetesStage: Phase 3Key result: 16.6% mean weight loss at 76 weeks versus 3.2% on placebo in 725 adultsWhy it matters: validates survodutide as a credible late-stage obesity contender, with potential differentiation through its glucagon componentGSK / Ionis — bepirovirsenMechanism: antisense oligonucleotide targeting hepatitis B viral RNAIndication: chronic hepatitis BStage: FDA Priority Review and Breakthrough Therapy designationKey result: Phase 3 studies showed significantly higher functional cure rates than standard of care, though full percentages were not disclosed todayWhy it matters: moves a potential functional-cure therapy into a defined FDA review window, with a PDUFA date of October 26, 2026Eli Lilly / Profluent — AI-designed recombinasesMechanism: site-specific recombinases for large-scale genome editingIndication: undisclosed severe genetic diseasesStage: research and preclinical collaborationKey result: deal worth up to $2.25 billion in milestones, plus tiered royaltiesWhy it matters: gives Lilly access to a platform aimed at long DNA insertion and whole-gene replacementScancell — iSCIB1+Mechanism: DNA ImmunoBody cancer vaccineIndication: advanced unresectable melanomaStage: Phase 2 update; FDA Fast Track designationKey result: 77% progression-free survival at 20 months versus a 43% historical benchmarkWhy it matters: strengthens the case for a registrational Phase 3 trial, while leaving randomized confirmation as the key riskTaiho / Cullinan — zipalertinibMechanism: oral irreversible EGFR inhibitorIndication: EGFR exon 20 insertion non-small cell lung cancer after platinum therapyStage: FDA NDA acceptedKey result: 35.2% confirmed response rate and 8.8-month median duration of response in 176 patientsWhy it matters: creates a clear regulatory catalyst in a difficult targeted lung cancer nicheToday’s stack: survodutide first, bepirovirsen second, Lilly-Profluent third, Scancell fourth, and zipalertinib fifth.

5 min
Episode 6

Wednesday, April 29: Survodutide’s Obesity Data, Teva’s Tourette Deal, and HER2 Gastric Review

BioBrief covers the key biotech and pharma moves from Wednesday, April 29, 2026. Today’s episode focuses on late-stage obesity data, a survival-positive HER2 gastric cancer filing, Teva’s neuroscience acquisition, and Immunome’s desmoid tumor NDA. Boehringer Ingelheim / Zealand Pharma — survodutideMechanism: Dual glucagon and GLP-1 receptor agonistIndication: Obesity or overweight without type 2 diabetesStage: Phase 3Key result: 16.6% body-weight loss at 76 weeks versus 3.2% on placebo in 725 adultsWhy it matters: Survodutide now looks like a credible late-stage obesity contender, with full data expected at ADA in June.BeOne Medicines / Jazz Pharmaceuticals — TEVIMBRA + ZIIHERA + chemotherapyMechanism: PD-1 antibody plus bispecific HER2 antibody plus chemotherapyIndication: First-line HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinomaStage: FDA Priority ReviewKey result: Median overall survival of 26.4 months versus 19.2 months for trastuzumab plus chemotherapy in 914 patientsWhy it matters: The regimen showed a clinically meaningful survival gain in a difficult first-line oncology setting.Teva / Emalex Biosciences — ecopipamMechanism: Selective dopamine D1 receptor antagonistIndication: Pediatric Tourette syndromeStage: NDA-readyKey result: Pediatric relapse rate of 41.9% on ecopipam versus 68.1% on placebo; hazard ratio of 0.5Why it matters: Teva is paying up to $900 million for a late-stage CNS asset that fits its innovative medicines strategy.Immunome — varegacestatMechanism: Oral gamma-secretase inhibitorIndication: Progressing desmoid tumorsStage: FDA NDA submittedKey result: 84% reduction in risk of progression or death versus placebo in 156 patients; response rate of 56% versus 9%Why it matters: The efficacy signal is strong, even if the commercial market is relatively small.Today’s stack: survodutide first, BeOne and Jazz second, Teva third, Immunome fourth.

6 min
Episode 7

Thursday, April 30: Axsome’s Alzheimer’s Approval, AstraZeneca’s Split ODAC, and uniQure’s UK Path

BioBrief covers the key biotech and pharma developments from Thursday, April 30, 2026. Axsome secured an FDA approval in Alzheimer’s agitation, AstraZeneca received a split advisory committee outcome across prostate and breast cancer, and uniQure advanced its Huntington’s gene therapy toward a UK filing. Axsome / AuvelityMechanism: NMDA receptor antagonism and sigma-1 receptor activity via dextromethorphan-bupropionIndication: Agitation associated with Alzheimer’s dementiaStage: FDA approvalKey result: ADVANCE-1 showed a 14.9-point agitation score improvement versus 11.6 on placebo at week fiveWhy it matters: Auvelity becomes the first approved non-antipsychotic for this use, with a June US launch expectedAstraZeneca / Truqap and camizestrantMechanism: Truqap is an AKT inhibitor; camizestrant is an oral SERDIndication: PTEN-deficient metastatic hormone-sensitive prostate cancer; HR-positive, HER2-negative breast cancer with ESR1 mutationStage: FDA advisory committee reviewsKey result: Truqap showed 33.2 months versus 25.7 months radiographic progression-free survival; camizestrant showed 16.0 months versus 9.2 months progression-free survivalWhy it matters: Advisers backed Truqap but rejected camizestrant’s benefit-risk case, showing how regulators are weighing biomarker-driven strategies differentlyuniQure / AMT-130Mechanism: AAV5 gene therapy delivering microRNA to lower huntingtinIndication: Huntington’s diseaseStage: Phase 1/2 package moving toward UK marketing applicationKey result: High-dose analysis suggested about 75% slowing versus an external matched controlWhy it matters: The UK path looks more open, but the evidence package remains non-standard and US regulatory risk remains highToday’s stack: Axsome first, AstraZeneca second, uniQure third.

6 min
Episode 8

Friday, May 1: Veppanu’s FDA Approval, Daraxonrasib Expanded Access, and Jakafi XR

BioBrief covers three high-signal biopharma developments from Friday, May 1, 2026. The FDA approved the first targeted protein degrader drug, Revolution Medicines moved closer to access in pancreatic cancer, and Incyte added a once-daily formulation to defend the Jakafi franchise. Arvinas / Pfizer — VeppanuMechanism: Oral estrogen receptor PROTAC / targeted protein degraderIndication: ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancerStage: FDA approvalKey result: Median progression-free survival of 5.0 months versus 2.1 months for fulvestrant in 270 ESR1-mutated patientsWhy it matters: First FDA-approved PROTAC, validating targeted protein degradation while raising launch questions in a narrow breast cancer labelRevolution Medicines — daraxonrasibMechanism: Oral RAS(ON) multi-selective inhibitorIndication: Previously treated metastatic pancreatic ductal adenocarcinomaStage: FDA expanded access clearanceKey result: Phase 3 median overall survival of 13.2 months versus 6.7 months for chemotherapy; hazard ratio 0.40Why it matters: Large survival signal in metastatic pancreatic cancer, with expanded access suggesting regulatory momentum before NDA filingIncyte — Jakafi XRMechanism: JAK1/JAK2 inhibitorIndication: Myelofibrosis, polycythemia vera, and graft-versus-host diseaseStage: FDA approvalKey result: Once-daily 55 mg extended-release formulation shown bioequivalent to 25 mg immediate-release twice dailyWhy it matters: Franchise-defense move for a multibillion-dollar hematology product, focused on convenience and retention rather than new efficacyToday’s stack: daraxonrasib first, Veppanu second, Jakafi XR third.

5 min

See All Season 1 (20)

BioBrief is a daily biotech and biopharma news update.

Creator

BioBrief
Episodes

20
Seasons

1
Rating

Clean
Copyright

© BioBrief 2026
Show Website

BioBrief